Latest news with #RocketPharmaceuticals
Business Insider
3 days ago
- Business
- Business Insider
LifeSci Capital Keeps Their Buy Rating on Rocket Pharmaceuticals (RCKT)
LifeSci Capital analyst Cory Jubinville, PhD maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $9.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Rocket Pharmaceuticals also received a Buy from Bank of America Securities's Jason Zemansky in a report issued on May 28. However, yesterday, Evercore ISI downgraded Rocket Pharmaceuticals (NASDAQ: RCKT) to a Hold. Based on Rocket Pharmaceuticals' latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $61.33 million. In comparison, last year the company had a GAAP net loss of $62.05 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year. Earlier this month, John Militello, the VP of Finance, Treasurer, Principal Accounting Officer of RCKT sold 357.00 shares for a total of $2,299.08.
Business Insider
3 days ago
- Business
- Business Insider
Liquidia Technologies (LQDA) Receives a Buy from LifeSci Capital
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $41.00. Confident Investing Starts Here: Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks. In addition to LifeSci Capital, Liquidia Technologies also received a Buy from H.C. Wainwright's Andrew Fein in a report issued on May 29. However, on May 19, Oppenheimer downgraded Liquidia Technologies (NASDAQ: LQDA) to a Sell.
Yahoo
5 days ago
- Business
- Yahoo
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease. The decision comes on the experimental drug RP-A501, resulting in a serious adverse event that led to a patient's demise. Likewise, Leerink Partners downgraded the stock to 'Market Perform' from an 'Outperform' and cut the price target to $8 from $37 on May 28. A successful investor with a portfolio including Finance Receivables, biotechnology, and medical device investments. The downgrade comes on Rocket Pharmaceutical recording its biggest slump in the market. The stock lost more than 50% in market value after the US Food and Drug Administration placed a hold on phase 2 trials for the candidate drug. Rocket Pharmaceuticals' webcast disclosed a serious adverse event (SAE), where a patient succumbed to acute systemic infection, leading to a clinical hold on the Phase 2 Danon disease program. It is a rare hereditary condition that results in gradual muscular weakening and damage to the heart muscle. Leerink Partners insists the company needs to address safety uncertainties and resolve clinical hold for a favorable rating. In addition, Leerink Partners insists that Rocket Pharmaceuticals faces an uphill task of re-establishing investor confidence. That's partly because the company needs to meet revised timelines for clinical programs, including LAD-I, Danon, and FA. Following the significant blow on the Danon Disease treatment, Rocket Pharmaceuticals has imploded to all-time lows. The stock is down by about 80% year to date. Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to developing gene therapies for rare and life-threatening diseases in the U.S., advancing adeno-associated viral (AAV) and lentiviral (LV) programs to target cardiac and immune disorders. Its AAV pipeline includes treatments for Danon disease (RP-A501, Phase 2), Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601, Phase 1), and BAG3 Dilated Cardiomyopathy (preclinical). At the same time, its LV platform develops therapies for Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102), and Pyruvate Kinase Deficiency (RP-L301), addressing critical immune and blood disorders. While we acknowledge the potential of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RCKT and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
6 days ago
- Business
- Yahoo
Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow
Rocket Pharmaceuticals, Inc.'s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt research on its experimental gene therapy for Danon Disease. The decision comes on the experimental drug RP-A501, resulting in a serious adverse event that led to a patient's demise. Likewise, Leerink Partners downgraded the stock to 'Market Perform' from an 'Outperform' and cut the price target to $8 from $37 on May 28. A successful investor with a portfolio including Finance Receivables, biotechnology, and medical device investments. The downgrade comes on Rocket Pharmaceutical recording its biggest slump in the market. The stock lost more than 50% in market value after the US Food and Drug Administration placed a hold on phase 2 trials for the candidate drug. Rocket Pharmaceuticals' webcast disclosed a serious adverse event (SAE), where a patient succumbed to acute systemic infection, leading to a clinical hold on the Phase 2 Danon disease program. It is a rare hereditary condition that results in gradual muscular weakening and damage to the heart muscle. Leerink Partners insists the company needs to address safety uncertainties and resolve clinical hold for a favorable rating. In addition, Leerink Partners insists that Rocket Pharmaceuticals faces an uphill task of re-establishing investor confidence. That's partly because the company needs to meet revised timelines for clinical programs, including LAD-I, Danon, and FA. Following the significant blow on the Danon Disease treatment, Rocket Pharmaceuticals has imploded to all-time lows. The stock is down by about 80% year to date. Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to developing gene therapies for rare and life-threatening diseases in the U.S., advancing adeno-associated viral (AAV) and lentiviral (LV) programs to target cardiac and immune disorders. Its AAV pipeline includes treatments for Danon disease (RP-A501, Phase 2), Plakophilin-2 Arrhythmogenic Cardiomyopathy (RP-A601, Phase 1), and BAG3 Dilated Cardiomyopathy (preclinical). At the same time, its LV platform develops therapies for Leukocyte Adhesion Deficiency-I (RP-L201), Fanconi Anemia (RP-L102), and Pyruvate Kinase Deficiency (RP-L301), addressing critical immune and blood disorders. While we acknowledge the potential of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RCKT and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) on Tuesday announced an update related to RP-A501, its investigational gene therapy for Danon disease, a rare X-linked dominant genetic disorder that manifests with the clinical triad of cardiomyopathy (stiff heart muscles), skeletal myopathy (weakness) and intellectual disability. A patient participating in the Phase 2 pivotal trial of RP-A501 experienced an unexpected Serious Adverse Event (SAE). The patient passed away after an acute systemic infection. Needham analyst Gil Blum downgraded Rocket Pharmaceuticals from Buy to Hold, with a Nil price forecast from $42 earlier. The analyst cited increased uncertainty around the company's main value driver as the key reason for the downgrade.'We continue to have a favorable view of RP-A501's efficacy; however, we see increased uncertainty for the product given safety concerns,' Blum said in an analyst note. Blum anticipates limited readthrough to Rocket's other AAV programs, which utilize simpler immunosuppression regimens. Chardan Research analyst Geulah Livshits also lowered its price target from $46 to $17 while maintaining the Buy rating. While the disclosure does not negate the benefit reported for the program, the patient death and commentary regarding instances of TMA impact the benefit/risk profile of RP-A501, Livshits said in an analyst note. Livshits reduced the probability of success from 70% to 40%, given CBER leadership's focus on benefit/risk, pending more details regarding agency feedback and next steps. The analyst projects a slower uptake among the Danon population (3.6% by 2030E), assuming greater caution among prescribers. Chardan notes the company hasn't revealed how many patients have been treated in the trial so far but said the study is currently over-enrolled, with more patients ready to begin treatment. Management mentioned several possible next steps, such as switching to a simpler immunomodulatory treatment, using existing complement inhibitors known to be safe, and continuing to exclude patients who are genetically predisposed to complement activation. Chardan highlights that it's still unclear whether other immunomodulatory treatments could reduce the risk of TMA. There's no timeline for when the company might align with the FDA and restart the trial. Additional changes like enrolling more patients may be required, which could cause further delays. Given this uncertainty, the topline results are expected to come later than the previously guided mid-2026 timeframe. Other analyst reactions: Jefferies downgraded Rocket Pharmaceuticals from Buy to Hold and lowered the price target from $29 to $2.5. Leerink Partners downgraded Rocket Pharmaceuticals from Outperform to Market Perform, lowering the price target from $37 to $8. Scotiabank maintains Rocket Pharmaceuticals with a Sector Outperform, lowering the price target from $51 to $19. Price Action: RCKT stock is trading higher by 6.44% to $2.48 at last check Wednesday. Read Next:Image via Shutterstock Date Firm Action From To Feb 2022 SVB Leerink Maintains Outperform Dec 2021 Chardan Capital Maintains Buy Aug 2021 SVB Leerink Maintains Outperform View More Analyst Ratings for RCKT View the Latest Analyst Ratings Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
